

From: [Michael Kane](#)
To: [Belfield, Erin K.](#); [Kelly Del Dotto](#); [Ahmed Davis](#); [Taylor Burgener](#); [Jacqueline Moran](#); [IPR51957-0001IP1](#)
Cc: [Kallas, Nicholas N.](#); [Schwarz, Christina](#); [Fishwick, Laura K.](#); [McJoynt, Alexis M.](#)
Subject: RE: IPR2023-01347 - Board Authorization to File Motion
Date: Wednesday, July 24, 2024 3:05:14 PM

Caution: External Email

Counsel,

In view of the disclaimer, Patent Owner dose not oppose.

Best regards,
Mike

From: Belfield, Erin K. <EKBelfield@Venable.com>
Sent: Thursday, July 18, 2024 11:07 AM
To: Michael Kane <kane@fr.com>; Kelly Del Dotto <allenspach.del.dotto@fr.com>; Ahmed Davis <Davis@fr.com>; Taylor Burgener <burgener@fr.com>; Jacqueline Moran <jtmoran@fr.com>; IPR51957-0001IP1 <IPR51957-0001IP1@fr.com>
Cc: nkallas@venable.com; cschwarz@venable.com; Fishwick, Laura K. <LFishwick@Venable.com>; McJoynt, Alexis M. <AMMcJoynt@Venable.com>
Subject: IPR2023-01347 - Board Authorization to File Motion

[This email originated outside of F&R.]

Counsel,

Novartis intends to seek authorization to file a Motion for Adverse Judgment in IPR2023-01347 in view of Patent Owners' disclaimer of the sole challenged claim. Please let us know by COB Tuesday, July 23, 2024 if Patent Owners oppose, and if so, whether you believe a meet and confer would be productive in resolving the dispute (as well as your availability for a meet and confer). Please also indicate Patent Owners' availability for a conference call with the Board, if needed, during the week of July 29th.

Kind regards,
Erin

[Erin K. Belfield](#) | Associate | [Venable LLP](#)
t 212.218.2143 | f 212.218.2200 | m 631.664.6164
151 W. 42nd Street, 49th Floor, New York, NY 10036

EKBelfield@Venable.com | www.Venable.com

This electronic mail transmission may contain confidential or privileged information. If you believe you have received this message in error, please notify the sender by reply transmission and delete the message without copying or disclosing it.

This email message is for the sole use of the intended recipient(s) and may contain confidential and privileged information. Any unauthorized use or disclosure is prohibited. If you are not the intended recipient, please contact the sender by reply email and destroy all copies of the original message.

